These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 17225204)

  • 1. [Dose reduction of conventional antipsychotics: does it reduce tardive dyskinesia?].
    van Berkel M; Bogers JP; Bouvy PF
    Tijdschr Psychiatr; 2007; 49(1):37-41. PubMed ID: 17225204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics.
    Freudenreich O; McEvoy JP
    J Clin Psychiatry; 1995 Apr; 56(4):173. PubMed ID: 7713860
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroleptic drugs: how to reduce the risk of tardive dyskinesia.
    DeVeaugh-Geiss J
    Geriatrics; 1979 Jul; 34(7):59-61, 66. PubMed ID: 36330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia rates with atypical antipsychotics in older adults.
    Jeste DV
    J Clin Psychiatry; 2004; 65 Suppl 9():21-4. PubMed ID: 15189108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atypical antipsychotics in the elderly].
    van Melick EJ;
    Tijdschr Gerontol Geriatr; 2004 Dec; 35(6):240-5. PubMed ID: 15704604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    Remington G
    Curr Opin Psychiatry; 2007 Mar; 20(2):131-7. PubMed ID: 17278910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():15-20. PubMed ID: 10739326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics.
    Rittmannsberger H
    Psychiatr Danub; 2008 Dec; 20(4):461-5. PubMed ID: 19011586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.
    Kane JM
    J Clin Psychiatry; 2004; 65 Suppl 9():16-20. PubMed ID: 15189107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients.
    Dolder CR; Jeste DV
    Biol Psychiatry; 2003 Jun; 53(12):1142-5. PubMed ID: 12814866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia clinic.
    Achimovich LM
    Aust N Z J Psychiatry; 1989 Mar; 23(1):15. PubMed ID: 2564769
    [No Abstract]   [Full Text] [Related]  

  • 14. Algorithms for neuroleptic-associated tardive movement disorders.
    Akiyama K
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S23-9. PubMed ID: 10560894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics.
    Rosenheck RA
    Br J Psychiatry; 2007 Sep; 191():238-45. PubMed ID: 17766765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of tardive dyskinesia.
    Kane JM; Woerner M; Lieberman JA; Weinhold P; Florio W; Rubinstein M; Rotrosen J; Kurucz J; Mukherjee S; Bergmann K
    Psychopharmacol Bull; 1985; 21(1):136-9. PubMed ID: 2858906
    [No Abstract]   [Full Text] [Related]  

  • 17. Overview: public health issues in tardive dyskinesia.
    Gardos G; Cole JO
    Am J Psychiatry; 1980 Jul; 137(7):776-81. PubMed ID: 6104443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro-effects of language on risk perception in drug prescribing behavior.
    Bursztajn HJ; Chanowitz B; Gutheil TG; Hamm RM
    Bull Am Acad Psychiatry Law; 1992; 20(1):59-66. PubMed ID: 1349499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
    Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
    Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.